Literature DB >> 27147545

Comparison of pathogenicity prediction tools on missense variants in RYR1 and CACNA1S associated with malignant hyperthermia.

A H Schiemann1, K M Stowell2.   

Abstract

BACKGROUND: Malignant hyperthermia (MH) is a pharmacogenetic disorder that has been linked to the skeletal muscle calcium release channel (RYR1) and the α1S subunit of the voltage-dependent L-type calcium channel (CACNA1S). Genomic DNA capture and next generation sequencing are becoming the preferred method to identify mutations in these genes. Bioinformatic pathogenicity prediction of identified variants may help to determine if these variants are in fact disease causing.
METHODS: Eight pathogenicity prediction programmes freely available on the web were used to determine their ability to correctly predict the impact of a missense variant on RyR1 or dihydropyridine receptor (DHPR) protein function. We tested MH-causative variants, variants that had been shown to alter calcium release in cells, and common sequence variants in RYR1 and CACNA1S.
RESULTS: None of the prediction programmes was able to identify all of the variants tested correctly as either 'damaging' (MH-causative variants, variants that had been shown to alter calcium release in cells) or as 'benign' (common sequence variants). The overall sensitivity of predictions ranged from 84% to 100% depending on the programme used, with specificity from 25% to 83%.
CONCLUSIONS: In this study we determined the sensitivity and specificity of bioinformatic pathogenicity prediction tools for RYR1 and CACNA1S. We suggest that the prediction results should be treated with caution, as none of the programmes tested predicted all the variants correctly and should only be used in combination with other available data (functional assays, segregation analysis).
© The Author 2016. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  bioinformatics; malignant hyperthermia; prediction; variants

Mesh:

Substances:

Year:  2016        PMID: 27147545      PMCID: PMC4913391          DOI: 10.1093/bja/aew065

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  23 in total

1.  Identification and functional characterization of malignant hyperthermia mutation T1354S in the outer pore of the Cavalpha1S-subunit.

Authors:  Antonella Pirone; Johann Schredelseker; Petronel Tuluc; Elvira Gravino; Giuliana Fortunato; Bernhard E Flucher; Antonella Carsana; Francesco Salvatore; Manfred Grabner
Journal:  Am J Physiol Cell Physiol       Date:  2010-09-22       Impact factor: 4.249

2.  Sequence-based prediction of pathological mutations.

Authors:  C Ferrer-Costa; M Orozco; X de la Cruz
Journal:  Proteins       Date:  2004-12-01

3.  Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information.

Authors:  E Capriotti; R Calabrese; R Casadio
Journal:  Bioinformatics       Date:  2006-08-07       Impact factor: 6.937

4.  Performance of mutation pathogenicity prediction methods on missense variants.

Authors:  Janita Thusberg; Ayodeji Olatubosun; Mauno Vihinen
Journal:  Hum Mutat       Date:  2011-02-22       Impact factor: 4.878

5.  Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.

Authors:  Nicole Monnier; Geneviève Kozak-Ribbens; Renée Krivosic-Horber; Yves Nivoche; Dong Qi; Natasha Kraev; Julian Loke; Parveen Sharma; Vincenzo Tegazzin; Dominique Figarella-Branger; Norma Roméro; Paulette Mezin; David Bendahan; Jean-François Payen; Thierry Depret; David H Maclennan; Joël Lunardi
Journal:  Hum Mutat       Date:  2005-11       Impact factor: 4.878

6.  A method and server for predicting damaging missense mutations.

Authors:  Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev
Journal:  Nat Methods       Date:  2010-04       Impact factor: 28.547

7.  Using exome data to identify malignant hyperthermia susceptibility mutations.

Authors:  Stephen G Gonsalves; David Ng; Jennifer J Johnston; Jamie K Teer; Peter D Stenson; David N Cooper; James C Mullikin; Leslie G Biesecker
Journal:  Anesthesiology       Date:  2013-11       Impact factor: 7.892

8.  Comparison of predicted and actual consequences of missense mutations.

Authors:  Lisa A Miosge; Matthew A Field; Yovina Sontani; Vicky Cho; Simon Johnson; Anna Palkova; Bhavani Balakishnan; Rong Liang; Yafei Zhang; Stephen Lyon; Bruce Beutler; Belinda Whittle; Edward M Bertram; Anselm Enders; Christopher C Goodnow; T Daniel Andrews
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-12       Impact factor: 11.205

9.  Compound RYR1 heterozygosity resulting in a complex phenotype of malignant hyperthermia susceptibility and a core myopathy.

Authors:  N Kraeva; L Heytens; H Jungbluth; S Treves; N Voermans; E Kamsteeg; C Ceuterick-de Groote; J Baets; S Riazi
Journal:  Neuromuscul Disord       Date:  2015-04-27       Impact factor: 4.296

Review 10.  The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine.

Authors:  Peter D Stenson; Matthew Mort; Edward V Ball; Katy Shaw; Andrew Phillips; David N Cooper
Journal:  Hum Genet       Date:  2014-01       Impact factor: 4.132

View more
  13 in total

1.  RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.

Authors:  Paul J Isackson; Jianxin Wang; Mohammad Zia; Paul Spurgeon; Adrian Levesque; Jonathan Bard; Smitha James; Norma Nowak; Tae Keun Lee; Georgirene D Vladutiu
Journal:  Pharmacogenomics       Date:  2018-10-16       Impact factor: 2.533

2.  Genetic epidemiology of malignant hyperthermia in the UK.

Authors:  D M Miller; C Daly; E M Aboelsaod; L Gardner; S J Hobson; K Riasat; S Shepherd; R L Robinson; J G Bilmen; P K Gupta; M-A Shaw; P M Hopkins
Journal:  Br J Anaesth       Date:  2018-08-17       Impact factor: 9.166

Review 3.  Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.

Authors:  Sheila Riazi; Natalia Kraeva; Philip M Hopkins
Journal:  Anesthesiology       Date:  2018-01       Impact factor: 7.892

4.  Myotoxicity of local anesthetics is equivalent in individuals with and without predisposition to malignant hyperthermia.

Authors:  Sachiko Otsuki; Toshimichi Yasuda; Keiko Mukaida; Yuko Noda; Rieko Kanzaki; Hirotsugu Miyoshi; Takashi Kondo; Hiroshi Hamada; Masashi Kawamoto
Journal:  J Anesth       Date:  2018-06-25       Impact factor: 2.078

5.  Assessing predictions of fitness effects of missense mutations in SUMO-conjugating enzyme UBE2I.

Authors:  Jing Zhang; Lisa N Kinch; Qian Cong; Jochen Weile; Song Sun; Atina G Cote; Frederick P Roth; Nick V Grishin
Journal:  Hum Mutat       Date:  2017-09       Impact factor: 4.878

6.  Development of pathogenicity predictors specific for variants that do not comply with clinical guidelines for the use of computational evidence.

Authors:  Elena Álvarez de la Campa; Natàlia Padilla; Xavier de la Cruz
Journal:  BMC Genomics       Date:  2017-08-11       Impact factor: 3.969

7.  Assessment of in silico protein sequence analysis in the clinical classification of variants in cancer risk genes.

Authors:  Iain D Kerr; Hannah C Cox; Kelsey Moyes; Brent Evans; Brianna C Burdett; Aric van Kan; Heather McElroy; Paris J Vail; Krystal L Brown; Dechie B Sumampong; Nicholas J Monteferrante; Kennedy L Hardman; Aaron Theisen; Erin Mundt; Richard J Wenstrup; Julie M Eggington
Journal:  J Community Genet       Date:  2017-01-03

8.  Novel Variants in Individuals with RYR1-Related Congenital Myopathies: Genetic, Laboratory, and Clinical Findings.

Authors:  Joshua J Todd; Muslima S Razaqyar; Jessica W Witherspoon; Tokunbor A Lawal; Ami Mankodi; Irene C Chrismer; Carolyn Allen; Mary D Meyer; Anna Kuo; Monique S Shelton; Kim Amburgey; Dmitriy Niyazov; Pierre Fequiere; Carsten G Bönnemann; James J Dowling; Katherine G Meilleur
Journal:  Front Neurol       Date:  2018-03-05       Impact factor: 4.003

9.  Annotation of Human Exome Gene Variants with Consensus Pathogenicity.

Authors:  Victor Jaravine; James Balmford; Patrick Metzger; Melanie Boerries; Harald Binder; Martin Boeker
Journal:  Genes (Basel)       Date:  2020-09-14       Impact factor: 4.096

10.  Efficacy of computational predictions of the functional effect of idiosyncratic pharmacogenetic variants.

Authors:  Hannah McConnell; T Daniel Andrews; Matt A Field
Journal:  PeerJ       Date:  2021-07-15       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.